Linköping, Sweden – October 2025 – In collaboration with Inaphaea Biolabs, Mount Sinai, and PopTest Palisades Therapeutics, BioReperia is proud to announce the presentation of groundbreaking work highlighting the ZTX® (Zebrafish Tumor Xenograft) platform as a powerful tool for accelerating and de-risking late preclinical oncology drug development.
This study has been published in the American Society of Clinical Oncology (ASCO) Journal of Clinical Oncology, under the title:
“Accelerating and De-risking Late Pre-clinical Drug Development with the Zebrafish Tumor Xenograft (ZTX®) Platform.”
Addressing the High Attrition Rate in Oncology Drug Development
Nearly 95% of oncology drug candidates fail during clinical development, often due to heterogeneous patient responses. To improve translational success, personalized preclinical testing is essential. Conventional models—such as mouse PDX and organoids—face limitations including low engraftment rates, high costs, and long development timelines.
The ZTX® Platform: A Rapid and Predictive Alternative
BioReperia’s ZTX® platform provides a rapid, cost-effective, and scalable solution for individualized drug-response profiling. Within just five days, the platform enables evaluation of drug efficacy and metastatic potential with sensitivity and specificity comparable to mouse PDX models, but at a fraction of the cost.
In this study:
- The ZTX® platform demonstrated high engraftment rates across multiple tumor types, including challenging indications such as glioblastoma.
- By distinguishing responders from non-responders within days, the platform supports precision oncology, biomarker discovery, and rational clinical trial design.
- Results revealed robust anti-metastatic activity of PT150 and synergistic effects of PT157 with enzalutamide, underscoring the platform’s translational value for AR/GR-driven prostate cancer.
Enabling the Future of Precision Oncology
With its combination of speed, predictive accuracy, and translational relevance, the ZTX® platform is emerging as a valuable companion tool for precision oncology and late-stage preclinical decision-making.
The publication is available here: https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.16_suppl.e15111
For more information, please contact:
Anna Erkstam
CEO, BioReperia AB
+46793322141
anna.erkstam@bioreperia.com